UPCOMING DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics due to allegations of false and misleading statements regarding its product SLK, which failed to demonstrate competitive efficacy compared to BIMZELX, leading to significant stock price decline [2][5][6][7]. Group 1: Legal Action and Deadlines - A federal securities class action has been filed against MoonLake, with a lead plaintiff deadline set for December 15, 2025 [2][8]. - Investors who suffered losses between March 10, 2024, and September 29, 2025, are encouraged to discuss their legal rights with Faruqi & Faruqi [1][2]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose critical information about the differences between Nanobodies and monoclonal antibodies [5]. - Specific allegations include claims that SLK's structure would not provide superior clinical benefits over BIMZELX and that its supposed increased tissue penetration would not lead to improved clinical efficacy [5]. Group 3: Stock Performance Impact - Following the announcement of disappointing Phase 3 VELA program results, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [6][7].